Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?
作者信息
Marchetti Claudia, Rosati Andrea, Scambia Giovanni, Fagotti Anna
机构信息
Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Catholic University of the Sacred Heart, Rome, Italy.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S372. doi: 10.21037/atm.2019.12.94.
Abstract
摘要
相似文献
1
Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?铂敏感复发性卵巢癌的二次肿瘤细胞减灭术：我们遗漏了什么吗？
Ann Transl Med. 2019 Dec;7(Suppl 8):S372. doi: 10.21037/atm.2019.12.94.
2
Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.二次细胞减灭术——铂类敏感复发性卵巢癌治疗的可行选择。
Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:154-160. doi: 10.1016/j.ejogrb.2018.06.036. Epub 2018 Jun 20.
3
Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.腹膜表面疾病严重程度评分（PSDSS）、AGO 评分和 TIAN 模型在接受细胞减灭术加 HIPEC 治疗的铂敏感复发性卵巢癌患者中的应用。
Clin Exp Metastasis. 2019 Oct;36(5):433-439. doi: 10.1007/s10585-019-09982-1. Epub 2019 Jul 3.
4
Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer.基于正电子发射断层扫描-腹腔镜检查的方法在预测铂敏感复发性卵巢癌完全肿瘤细胞减灭术中的应用
Ann Surg Oncol. 2015 Feb;22(2):649-54. doi: 10.1245/s10434-014-4011-0. Epub 2014 Aug 26.
5
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.复发性铂敏感上皮性卵巢癌患者二次减瘤手术的指南和选择标准。
Cancer. 2006 May 1;106(9):1933-9. doi: 10.1002/cncr.21845.
6
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.紫杉醇腹腔热灌注化疗在铂敏感复发性上皮性卵巢癌患者减瘤术后微小残留病灶中的作用。
Ann Surg Oncol. 2015 Mar;22(3):987-93. doi: 10.1245/s10434-014-4049-z. Epub 2014 Sep 12.
7
Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.微创二次肿瘤细胞减灭术联合腹腔热灌注化疗与开放性手术联合腹腔热灌注化疗治疗卵巢癌孤立性复发的比较：一项关于围手术期结局的回顾性队列研究
J Minim Invasive Gynecol. 2015 Mar-Apr;22(3):428-32. doi: 10.1016/j.jmig.2014.11.008. Epub 2014 Nov 26.
8
Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience.复发性卵巢癌的二次腹腔镜肿瘤细胞减灭术：一项大型单机构经验。
J Minim Invasive Gynecol. 2018 May-Jun;25(4):644-650. doi: 10.1016/j.jmig.2017.10.024. Epub 2017 Nov 13.
9
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.铂敏感复发性卵巢癌老年患者的不良预后：苏格拉底回顾性研究结果
Crit Rev Oncol Hematol. 2009 Sep;71(3):233-41. doi: 10.1016/j.critrevonc.2008.12.010. Epub 2009 Jan 28.
10
HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.HIPEC ROC I：一项关于顺铂的I期研究，该研究针对铂敏感复发性上皮性卵巢癌患者，在术中进行高温腹腔内化疗灌注顺铂，术后进行静脉铂类化疗。
Int J Cancer. 2015 Feb 1;136(3):699-708. doi: 10.1002/ijc.29011. Epub 2014 Jun 17.
引用本文的文献
1
Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.铂敏感复发性卵巢癌二次肿瘤细胞减灭术的最新进展：一项叙述性综述
Ann Transl Med. 2021 Mar;9(6):510. doi: 10.21037/atm-20-4690.
2
Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.丹参酮IIA通过抑制恶性特性和血管生成来抑制卵巢癌生长。
Ann Transl Med. 2020 Oct;8(20):1295. doi: 10.21037/atm-20-5741.
3
Surgery chemotherapy for ovarian cancer recurrence: what is the best treatment option.卵巢癌复发的手术及化疗：最佳治疗方案是什么。
Gland Surg. 2020 Aug;9(4):1112-1117. doi: 10.21037/gs-20-326.
4
Role of ultrasound in the detection of recurrent ovarian cancer: a review of the literature.超声在复发性卵巢癌检测中的作用：文献综述
Gland Surg. 2020 Aug;9(4):1092-1101. doi: 10.21037/gs-20-357.
5
Natural compound Tan-I enhances the efficacy of Paclitaxel chemotherapy in ovarian cancer.天然化合物Tan-I增强了紫杉醇化疗对卵巢癌的疗效。
Ann Transl Med. 2020 Jun;8(12):752. doi: 10.21037/atm-20-4072.
本文引用的文献
1
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.奥拉帕利维持治疗前铂类敏感复发性卵巢癌的二次细胞减灭术：仍能获益吗？一项病例对照研究。
Gynecol Oncol. 2019 Dec;155(3):400-405. doi: 10.1016/j.ygyno.2019.09.020. Epub 2019 Oct 9.
2
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
3
Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.铂敏感复发性卵巢癌患者二次细胞减灭术后的结局。
Am J Obstet Gynecol. 2019 Dec;221(6):625.e1-625.e14. doi: 10.1016/j.ajog.2019.06.009. Epub 2019 Jun 14.
4
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.奥拉帕利维持治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
5
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.BRCA 基因突变状态与复发性卵巢癌的个体化管理：一项多中心研究。
Ann Surg Oncol. 2018 Nov;25(12):3701-3708. doi: 10.1245/s10434-018-6700-6. Epub 2018 Aug 20.
6
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
7
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.芦卡帕利维持治疗铂类化疗后缓解的复发性卵巢癌（ARIEL3）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.
8
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.奥拉帕利片作为 BRCA1/2 突变的铂敏感复发性卵巢癌患者的维持治疗（SOLO2/ENGOT-Ov21）：一项双盲、随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.
9
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.尼拉帕利维持治疗铂敏感复发性卵巢癌。
N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7.
10
The role of secondary surgery in recurrent ovarian cancer.二次手术在复发性卵巢癌中的作用。
Int J Surg Oncol. 2012;2012:613980. doi: 10.1155/2012/613980. Epub 2012 Aug 5.
Zotero 插件